. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease. Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.